Immunotherapy plus chemotherapy before surgery improves outcomes for lung cancer patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC)—the leading cause of cancer deaths worldwide—reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial. It also achieved a nearly twelvefold increase in pathological complete response—meaning no active cancer remaining when the tumor was removed—over patients who received chemotherapy alone.
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC)—the leading cause of cancer deaths worldwide—reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial. It also achieved a nearly twelvefold increase in pathological complete response—meaning no active cancer remaining when the tumor was removed—over patients who received chemotherapy alone.